Virtual Tumor Board®: Diagnosis and Management of Polycythemia Vera and Myelofibrosis

Virtual Tumor Board®: Diagnosis and Management of Polycythemia Vera and Myelofibrosis is organized by Physicians' Education Resource, LLC (PER) and will be held from Feb 28, 2019 - Feb 28 2020. This Course has been approved for a maximum of CME: 1.5, CNE: 1.5.

Target Audience:
This educational activity is directed toward hematologists and medical oncologists, as well as fellows involved in the treatment and management of patients with MPNs. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of MPNs may also participate.

Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Discuss recent developments in molecular diagnostics and their impact on therapeutic decision-making in the management of myelofibrosis (MF) and polycythemia vera (PV)
• Describe the mechanistic rationale for overlap of MF and PV therapeutic approaches in the context of the current treatment landscape
• Evaluate clinical trial data on emerging agents and regimens to treat MF and PV
• Integrate recent trial findings to optimize clinical decision-making and care for patients with MF and PV

Activity Overview:
We are pleased to present this CME-certified activity, a PER® Live Virtual Tumor Board®: Advancing Polycythemia Vera and Myelofibrosis Enduring CME Activity. This activity is an enduring version of the live Virtual Tumor Board® originally presented by PER® at www.gotoper.com on February 21, 2019, at 8:00 PM EST.

This program explores current trends in the prognostic scoring, molecular diagnostic studies, and appropriate guideline-based management of myeloproliferative neoplasms (MPNs), as well as current and emerging therapeutic strategies across MPNs. By applying evidence in real-world case scenarios, this program contextualizes that evidence to ensure that practitioners are up-to-date with recent developments in molecular diagnostics, the effect of diagnostic techniques on therapeutic decision-making, current clinical trial findings, evolving treatment paradigms, and the mechanistic rationale for novel therapeutic approaches in the context of MPN pathophysiology.

Additional details will be posted as soon as they are available.